Navigation Links
EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
Date:11/10/2008

ibition of the mTOR/rictor pathway. The Akt-mTOR pathway is the most frequently mutated pathway in human tumors and mutations have been shown to promote tumor progression and decrease survival in cancer patients. EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., commented on the study, "We are pleased to have met the primary efficacy endpoint in the first stage of this study. We are now considering whether to continue the current study or pursue additional options such as a randomized Phase 2 study in patients with non-small cell lung cancer. We will continue to collect data over the next few months from patients participating in this trial to determine the most efficient path forward in this indication."

Alimta(R) is a registered trademark of its owner and is not a registered trademark of EntreMed, Inc.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Pr
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
2. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
5. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
6. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
7. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
8. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
9. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
10. World Think Tank on Type 1 Diabetes Meets in Miami
11. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... proprietary technologies are used to discover, develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... as Vice President and Chief Financial Officer. Tom ... information technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... anthrax that is more effective and easier to administer than ... mice and guinea pigs, report University of Michigan Medical School ... , The scientists were able to trigger a strong immune ... a nanoemulsion a suspension of water, soybean oil, alcohol ...
... engineers assemble spacecraft, have joined hot springs, ice ... scientists have discovered ultra-hardy organisms collectively known as ... recent NASA study have never been detected anywhere ... led the study conducted at NASAs Jet Propulsion ...
... method for culturing mammalian neurons in chambers not much larger ... of the neurons at very low densities, an essential step ... of individual brain cells. , The technique is described this ... Lab on a Chip. , This finding will be ...
Cached Biology Technology:Anthrax vaccine produces immunity with nanoparticles, not needles 2Anthrax vaccine produces immunity with nanoparticles, not needles 3NASA study will help stop stowaways to Mars 2Microfluidic chambers advance the science of growing neurons 2Microfluidic chambers advance the science of growing neurons 3
(Date:7/30/2014)... University Press (OUP) is pleased to announce its new ... in 2015, OUP and CINP will partner to publish ... as a fully open-access journal. , Alan Frazer, Editor-in-Chief ... the size and expertise of OUP will further facilitate ... one of the very leading journals within neuropsychopharmacology. The ...
(Date:7/30/2014)... York , July 30, 2014 ... on Global Government Biometric Systems Market 2014-2024 ... The Global Biometric Systems Market 2014-2024" offers ... systems market over the next ten years, alongside ... detailed market size forecasts. To view ...
(Date:7/30/2014)... help Americans make better decisions about what they eat, ... proposed significant changes to the Nutrition Facts label found ... article in Chemical & Engineering News (C&EN), ... explains the suggested updates and the fight that ... C&EN, points out that while the Nutrition Facts label ...
Breaking Biology News(10 mins):OUP to partner with the International College of Neuropsychopharmacology 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... bird in hand is worth two in the bush may ... the lab of ASU School of Life Sciences Professor Roy ... at the Biodesign Institute. There, associate research scientist ... targets to develop a vaccine against a leading poultry disease, ...
... working gene is inserted into a cell to replace a ... the prevention and treatment of disease. Now a ... a counterintuitive approach also holds promise. The targeted removal of ... would do -- can restore cellular function in cells with ...
... United Kingdom and France have identified four separate ... Creutzfeldt-Jakob disease. The study, published March 14th in ... subgroups could represent distinct prion strains in what ... Prion diseases are transmissible neurodegenerative disorders characterized by ...
Cached Biology News:Solving an avian scourge could also provide benefits to human health 2Solving an avian scourge could also provide benefits to human health 3Work with power grids leads to cell biology discovery 2Work with power grids leads to cell biology discovery 3
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Reacts with methylated DNA from plants and vertebrates...
Biology Products: